Celonis Opens New Offices in Denmark and Sweden to Accelerate Value Creation through Process Mining for Customers in the Nordics
23.8.2023 11:00:00 EEST | Business Wire | Press release
Celonis, the global leader in Process Mining, today announced the opening of its new offices in Copenhagen, Denmark and Stockholm, Sweden. The launch of these new sites bolsters Celonis’ existing operations and adoption for its market leading process mining technology in the Nordics.
Celonis’ investment in the region is a reflection of the enormous demand for value creating technologies from Nordics’ businesses, especially in the areas of manufacturing and IT both of which have already greatly benefited from process mining.
Since starting operations in the Nordics about three years ago, Celonis has grown to more than 40 employees and more than 70 customers, including some of the most innovative and well-known companies in the Nordics such as Nokia, Telia and Equinor.
The opening of the new Swedish office overlooking Norrmalmstorg will be honored with a ribbon-cutting ceremony and a cocktail reception for prospects, partners and customers. Bastian Nominacher, co-CEO and co-founder of Celonis, will be in attendance to deliver a speech.
“The new Stockholm and Copenhagen offices are important steps in our mission to bring the value of process mining to customers across all regions and industries,” said Nominacher. “Our strengthened presence in the Nordics enables us to accelerate process mining adoption for enterprises in the Nordics. We look forward to helping organizations in the region yield immediate cash impact and radically improve customer experience. Furthermore, the Nordic countries have a strong focus on environmentalism and sustainability, and Celonis has a proven track record of helping customers reduce carbon emissions. We will leverage our process mining technology, to enable customers in the region to perform at levels they never thought possible.”
“These new office locations are a clear commitment to Celonis’ expansion in the Nordics,” said Michael Zink, Regional Vice President and General Manager of the Nordics at Celonis. “This region has many companies focused on driving innovation, with a well-educated and skilled workforce. Ingenuity and sustainability also go hand in hand in the Nordics. Our market leading process mining technology will accelerate business performance for companies in the region, delivering fast and sustainable value that support the innovation and sustainability ethos found throughout organizations here in the Nordics.”
Mikael Schwarzman, Sales Director & Country Leader at Celonis, has been named Site Leader in the Stockholm office and will oversee operations across Sweden. Sales Director Karsten Mayland is Site Leader for the Copenhagen office.
This office opening follows Celonis being named leader of the first-ever 2023 Gartner® Magic Quadrant™ for Process Mining Tools, as well as leader in the Everest Group PEAK Matrix® for Process Mining for the fourth year in a row.
About Celonis
Celonis enables customers to optimize their business processes. Powered by its leading process mining technology, Celonis provides a unique set of capabilities for business executives and users to continuously find improvement opportunities within and across processes, and execute targeted actions to rapidly enhance process performance. This optimization yields immediate cash impact, radically improves customer experience, and reduces carbon emissions. Celonis has thousands of implementations with global customers and is headquartered in Munich, Germany and New York City, USA with more than 20 offices worldwide.
© 2023 Celonis SE. All rights reserved. Celonis, Execution Management System, EMS, Process Sphere and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823526175/en/
Contact information
Celonis
press@celonis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom